234 related articles for article (PubMed ID: 31208914)
1. Substrate Reduction Therapy for Sandhoff Disease through Inhibition of Glucosylceramide Synthase Activity.
Marshall J; Nietupski JB; Park H; Cao J; Bangari DS; Silvescu C; Wilper T; Randall K; Tietz D; Wang B; Ying X; Leonard JP; Cheng SH
Mol Ther; 2019 Aug; 27(8):1495-1506. PubMed ID: 31208914
[TBL] [Abstract][Full Text] [Related]
2. Iminosugar-based inhibitors of glucosylceramide synthase increase brain glycosphingolipids and survival in a mouse model of Sandhoff disease.
Ashe KM; Bangari D; Li L; Cabrera-Salazar MA; Bercury SD; Nietupski JB; Cooper CG; Aerts JM; Lee ER; Copeland DP; Cheng SH; Scheule RK; Marshall J
PLoS One; 2011; 6(6):e21758. PubMed ID: 21738789
[TBL] [Abstract][Full Text] [Related]
3. CNS-accessible Inhibitor of Glucosylceramide Synthase for Substrate Reduction Therapy of Neuronopathic Gaucher Disease.
Marshall J; Sun Y; Bangari DS; Budman E; Park H; Nietupski JB; Allaire A; Cromwell MA; Wang B; Grabowski GA; Leonard JP; Cheng SH
Mol Ther; 2016 Jun; 24(6):1019-1029. PubMed ID: 26948439
[TBL] [Abstract][Full Text] [Related]
4. Iminosugar-based inhibitors of glucosylceramide synthase prolong survival but paradoxically increase brain glucosylceramide levels in Niemann-Pick C mice.
Nietupski JB; Pacheco JJ; Chuang WL; Maratea K; Li L; Foley J; Ashe KM; Cooper CG; Aerts JM; Copeland DP; Scheule RK; Cheng SH; Marshall J
Mol Genet Metab; 2012 Apr; 105(4):621-8. PubMed ID: 22366055
[TBL] [Abstract][Full Text] [Related]
5. [Molecular pathogenesis and therapeutic approach of GM2 gangliosidosis].
Tsuji D
Yakugaku Zasshi; 2013; 133(2):269-74. PubMed ID: 23370522
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of Enzyme and Substrate Reduction Therapy with a Novel Antagonist of Glucosylceramide Synthase for Fabry Disease.
Ashe KM; Budman E; Bangari DS; Siegel CS; Nietupski JB; Wang B; Desnick RJ; Scheule RK; Leonard JP; Cheng SH; Marshall J
Mol Med; 2015 Apr; 21(1):389-99. PubMed ID: 25938659
[TBL] [Abstract][Full Text] [Related]
7. Miglustat therapy in juvenile Sandhoff disease.
Tallaksen CM; Berg JE
J Inherit Metab Dis; 2009 Dec; 32 Suppl 1():S289-93. PubMed ID: 19898953
[TBL] [Abstract][Full Text] [Related]
8. Substrate reduction therapy with miglustat in chronic GM2 gangliosidosis type Sandhoff: results of a 3-year follow-up.
Masciullo M; Santoro M; Modoni A; Ricci E; Guitton J; Tonali P; Silvestri G
J Inherit Metab Dis; 2010 Dec; 33 Suppl 3():S355-61. PubMed ID: 20821051
[TBL] [Abstract][Full Text] [Related]
9. Systemic Gene Transfer of a Hexosaminidase Variant Using an scAAV9.47 Vector Corrects GM2 Gangliosidosis in Sandhoff Mice.
Osmon KJ; Woodley E; Thompson P; Ong K; Karumuthil-Melethil S; Keimel JG; Mark BL; Mahuran D; Gray SJ; Walia JS
Hum Gene Ther; 2016 Jul; 27(7):497-508. PubMed ID: 27199088
[TBL] [Abstract][Full Text] [Related]
10. Delayed symptom onset and increased life expectancy in Sandhoff disease mice treated with N-butyldeoxynojirimycin.
Jeyakumar M; Butters TD; Cortina-Borja M; Hunnam V; Proia RL; Perry VH; Dwek RA; Platt FM
Proc Natl Acad Sci U S A; 1999 May; 96(11):6388-93. PubMed ID: 10339597
[TBL] [Abstract][Full Text] [Related]
11. Long-term correction of Sandhoff disease following intravenous delivery of rAAV9 to mouse neonates.
Walia JS; Altaleb N; Bello A; Kruck C; LaFave MC; Varshney GK; Burgess SM; Chowdhury B; Hurlbut D; Hemming R; Kobinger GP; Triggs-Raine B
Mol Ther; 2015 Mar; 23(3):414-22. PubMed ID: 25515709
[TBL] [Abstract][Full Text] [Related]
12. Glucosylceramide synthase inhibitors prevent replication of SARS-CoV-2 and influenza virus.
Vitner EB; Achdout H; Avraham R; Politi B; Cherry L; Tamir H; Yahalom-Ronen Y; Paran N; Melamed S; Erez N; Israely T
J Biol Chem; 2021; 296():100470. PubMed ID: 33639165
[TBL] [Abstract][Full Text] [Related]
13. Reversion of the biochemical defects in murine embryonic Sandhoff neurons using a bicistronic lentiviral vector encoding hexosaminidase alpha and beta.
Arfi A; Zisling R; Richard E; Batista L; Poenaru L; Futerman AH; Caillaud C
J Neurochem; 2006 Mar; 96(6):1572-9. PubMed ID: 16441513
[TBL] [Abstract][Full Text] [Related]
14. Genetics and Therapies for GM2 Gangliosidosis.
Cachon-Gonzalez MB; Zaccariotto E; Cox TM
Curr Gene Ther; 2018; 18(2):68-89. PubMed ID: 29618308
[TBL] [Abstract][Full Text] [Related]
15. The GM2 gangliosidoses: Unlocking the mysteries of pathogenesis and treatment.
Toro C; Zainab M; Tifft CJ
Neurosci Lett; 2021 Nov; 764():136195. PubMed ID: 34450229
[No Abstract] [Full Text] [Related]
16. Brain endothelial specific gene therapy improves experimental Sandhoff disease.
Dogbevia G; Grasshoff H; Othman A; Penno A; Schwaninger M
J Cereb Blood Flow Metab; 2020 Jun; 40(6):1338-1350. PubMed ID: 31357902
[TBL] [Abstract][Full Text] [Related]
17. Protease-resistant modified human β-hexosaminidase B ameliorates symptoms in GM2 gangliosidosis model.
Kitakaze K; Mizutani Y; Sugiyama E; Tasaki C; Tsuji D; Maita N; Hirokawa T; Asanuma D; Kamiya M; Sato K; Setou M; Urano Y; Togawa T; Otaka A; Sakuraba H; Itoh K
J Clin Invest; 2016 May; 126(5):1691-703. PubMed ID: 27018595
[TBL] [Abstract][Full Text] [Related]
18. N-butyldeoxygalactonojirimycin reduces brain ganglioside and GM2 content in neonatal Sandhoff disease mice.
Baek RC; Kasperzyk JL; Platt FM; Seyfried TN
Neurochem Int; 2008 May; 52(6):1125-33. PubMed ID: 18207611
[TBL] [Abstract][Full Text] [Related]
19. Plasmid-based gene transfer ameliorates visceral storage in a mouse model of Sandhoff disease.
Yamaguchi A; Katsuyama K; Suzuki K; Kosaka K; Aoki I; Yamanaka S
J Mol Med (Berl); 2003 Mar; 81(3):185-93. PubMed ID: 12682727
[TBL] [Abstract][Full Text] [Related]
20. Lyso-GM2 ganglioside: a possible biomarker of Tay-Sachs disease and Sandhoff disease.
Kodama T; Togawa T; Tsukimura T; Kawashima I; Matsuoka K; Kitakaze K; Tsuji D; Itoh K; Ishida Y; Suzuki M; Suzuki T; Sakuraba H
PLoS One; 2011; 6(12):e29074. PubMed ID: 22205997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
